Published On: October 29th, 2010
Vivus said it will respond to the FDA in about six weeks.

Original post:
FDA Nixes Vivus’s Qnexa; Asks For More Safety Data
STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.
Loading...
Did you know:
Female breast cancer: 125.5 per 100,000 deaths in women per year
-
carybyrd : FDA in line for new foreign-inspection powers - FiercePharma http://t.co/1UG4NONb2012-05-22T19:11:28Z - Reply - View Tweet
-
liatarle234 : entericcoated aspirin List Of Recommended Online Pharmacies: => Online Pharmacy 1 (FDA Approved medications) http://t.co/hpT75Q6r2012-05-22T19:11:25Z - Reply - View Tweet
-
PharmaSy : Prescription Errors are Tough to Swallow http://t.co/bPvSo4On2012-05-22T19:11:20Z - Reply - View Tweet
-
healthlawyers : Bloom's response on scientific exchange: Maybe industry paying for egregious examples in past. Distinction tween FDA and DOJ enforcem action2012-05-22T19:11:06Z - Reply - View Tweet
-
VistaPResearch : $OHRP FDA Grants Fast Track Designation to Ohr Pharmaceutical's Squalamine Eye Drops for the Treatment of #Wet-AMD http://t.co/JgQ9ijg62012-05-22T19:11:01Z - Reply - View Tweet
-
CBRPharma : FDA?s $6.4 Billion Plan for Quick Reviews Moves to Senate - Bloomberg http://t.co/yThzZftV2012-05-22T19:11:00Z - Reply - View Tweet
-
liatarle234 : enteric coated aspirin side effects List Of Recommended Online Pharmacies: => Online Pharmacy 1 (FDA Approve http://t.co/GQT5cpCb2012-05-22T19:10:50Z - Reply - View Tweet
Related Posts
- FDA Panel Rejects Vivus’s Qnexa, Citing Safety Worries
Two other anti-obesity drugs are up for FDA approval. .. - Qnexa Trial Data is Good News for Vivus as Stock Rises
The past several months have not been particularly jolly for three experimental weight-loss drugs and their manufacturers, Vivus, Orexigen and Arena. One by one, the drugs have failed to be approved by the FDA without additional supporting data, slapping down the hopes of patients and investors that there’d finally be a new medical treatment for.. - A.M. Vitals: FDA Wants More Data on Diabetes Drug from Bristol-Myers, AstraZeneca
Seeking More Data: The FDA wants more information about an experimental diabetes drug from Bristol-Myers Squibb and AstraZeneca before considering it for approval, Dow Jones Newswires reports . The companies said the agency wants more clinical data in order to better assess the risks and benefits of dapagliflozin, which is a new type of therapy.. - Avandia, Qnexa Mean a Big Week for FDA Advisory Committee
The resolution to the Avandia brouhaha will be seen as an indicator of how the FDA’s new leadership handles safety concerns about drugs that are already on the market. .. - What’s a Data and Safety Monitoring Board, Anyway?
Merck’s recent announcement about trials of an experimental anti-clotting drug has highlighted the role of data and safety monitoring boards. .. - Hail Mary Pass? Group Asks Pope to Block Hospital Sale to Cerberus
Will the Pope sign off on a private-equity deal? ..
Leave a comment








